Novo Nordisk Invests €432M in Wegovy Pill
Novo Nordisk is investing over €432 million to upgrade its Irish facility to produce an oral version of its blockbuster obesity drug, Wegovy. The move aims to secure non-US production capacity as competition heats up, particularly from Chinese biotech QL Biopharm, which just raised $72 million to advance its own GLP-1 drug.
The global market for obesity drugs is projected to explode, with some forecasts suggesting it could reach $105 billion by 2030, a significant increase from $6 billion in 2023. This growth is driven by a new class of drugs, GLP-1 agonists, which have demonstrated significant effectiveness in weight loss and are expanding their use to treat related health conditions. Some analysts predict the market could be worth as much as $200 billion by 2031. Novo Nordisk's oral semaglutide, the pill version of Wegovy, showed impressive results in its OASIS 4 Phase III trial, with participants achieving a mean weight loss of 16.6% after 64 weeks with full adherence. One-third of participants in the trial who were fully adherent lost 20% or more of their body weight. The U.S. FDA approved the oral version of Wegovy in December 2025, with a full American launch in January 2026. The investment in the Athlone, Ireland facility is a strategic move to establish a crucial manufacturing hub for markets outside the U.S. This expansion, expected to be completed in phases between late 2027 and 2028, aims to build resilience in the global supply chain for Novo Nordisk's oral GLP-1 treatments. The project will upgrade the existing 45-acre site and is anticipated to create up to 500 construction jobs. Eli Lilly has emerged as a formidable competitor with its own oral GLP-1 candidate, orforglipron. In a head-to-head Phase 3 trial, orforglipron demonstrated superior blood sugar control and weight loss compared to Novo Nordisk's oral semaglutide in adults with type 2 diabetes. To avoid the supply shortages that plagued the initial launches of injectable GLP-1 drugs, Eli Lilly has already stockpiled $1.5 billion worth of orforglipron ahead of its anticipated launch. The shift to oral medications represents a significant development in the obesity treatment landscape, offering greater convenience and potentially increasing patient adherence. However, producing oral versions of these complex peptide drugs is challenging and expensive, requiring significantly more active pharmaceutical ingredient (API) due to low bioavailability. This manufacturing complexity underscores the strategic importance of investments like Novo Nordisk's in its Irish facility.
